Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice.

Mulligan CM, Harper R, Harding J, McIlwaine W, Petruckevitch A, McLaughlin DM.

Diabetes Ther. 2013 Jun;4(1):147-51. doi: 10.1007/s13300-013-0025-z. Epub 2013 May 29.

2.

Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.

Lapolla A, Frison V, Bettio M, Dal Pos M, Rocchini P, Panebianco G, Tadiotto F, Da Tos V, D'Ambrosio M, Marangoni A, Ferrari M, Pianta A, Balzano S, Confortin L, Lamonica M, Marin N, Strazzabosco M, Brun E, Mesturino CA, Simoncini M, Zen F, Bax G, Bonsembiante B, Cardone C, Dal Frà MG, Gallo A, Masin M, Piarulli F, Sartore G, Simioni N.

Clin Ther. 2015 Mar 1;37(3):574-84. doi: 10.1016/j.clinthera.2014.11.015. Epub 2015 Jan 24.

PMID:
25626486
3.

Long-term effectiveness and safety of liraglutide in clinical practice.

Ponzani P.

Minerva Endocrinol. 2013 Mar;38(1):103-12.

PMID:
23435446
4.

The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.

Lane W, Weinrib S, Rappaport J.

Diabetes Technol Ther. 2011 May;13(5):592-5. doi: 10.1089/dia.2010.0221. Epub 2011 Mar 15.

PMID:
21406014
5.

Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.

Berkovic MC, Bilic-Curcic I, Herman Mahecic D, Gradiser M, Grgurevic M, Bozek T.

Diabetes Ther. 2017 Dec;8(6):1297-1308. doi: 10.1007/s13300-017-0324-x. Epub 2017 Oct 26.

6.

Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.

Feher M, Vega-Hernandez G, Mocevic E, Buysse B, Myland M, Power GS, Nystrup Husemoen LL, Kim J, Witte DR.

Diabetes Ther. 2017 Apr;8(2):417-431. doi: 10.1007/s13300-017-0241-z. Epub 2017 Mar 9.

7.

Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.

Bode BW, Brett J, Falahati A, Pratley RE.

Am J Geriatr Pharmacother. 2011 Dec;9(6):423-33. doi: 10.1016/j.amjopharm.2011.09.007. Epub 2011 Nov 4.

PMID:
22055210
8.

Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.

Lapolla A, Berra C, Boemi M, Bossi AC, Candido R, Di Cianni G, Frontoni S, Genovese S, Ponzani P, Provenzano V, Russo GT, Sciangula L, Simioni N, Bette C, Nicolucci A; NN2211-4118 Study Group.

Adv Ther. 2017 Dec 21. doi: 10.1007/s12325-017-0652-2. [Epub ahead of print]

PMID:
29270781
9.

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.

Nauck MA, Petrie JR, Sesti G, Mannucci E, Courrèges JP, Lindegaard ML, Jensen CB, Atkin SL; Study 1821 Investigators.

Diabetes Care. 2016 Feb;39(2):231-41. doi: 10.2337/dc15-0165. Epub 2015 Sep 10.

PMID:
26358288
11.

Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting.

Kaur P, Mahendru S, Mithal A.

Indian J Endocrinol Metab. 2016 Sep-Oct;20(5):595-599.

12.
13.

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

Dungan KM, Povedano ST, Forst T, González JG, Atisso C, Sealls W, Fahrbach JL.

Lancet. 2014 Oct 11;384(9951):1349-57. doi: 10.1016/S0140-6736(14)60976-4. Epub 2014 Jul 10. Erratum in: Lancet. 2014 Oct 11:384(9951):1348.

PMID:
25018121
14.

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.

Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, Jensen T, Jensen AK, Holst JJ, Tarnow L, Knop FK, Madsbad S, Andersen HU.

Lancet Diabetes Endocrinol. 2016 Mar;4(3):221-32. doi: 10.1016/S2213-8587(15)00436-2. Epub 2015 Dec 3.

PMID:
26656289
15.

A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice.

Evans M, McEwan P, O'Shea R, George L.

Diabetes Ther. 2013 Jun;4(1):27-40. doi: 10.1007/s13300-012-0015-6. Epub 2012 Dec 8.

16.
17.
18.
19.

Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.

Ostawal A, Mocevic E, Kragh N, Xu W.

Diabetes Ther. 2016 Sep;7(3):411-38. doi: 10.1007/s13300-016-0180-0. Epub 2016 Jun 27. Review.

20.

Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients.

Ghuman NK, Saadah LM, Al Najjar MS, Shaheen DY, Am SI, Al Ali MM.

Clin Med Insights Endocrinol Diabetes. 2015 Sep 20;8:67-72. doi: 10.4137/CMED.S31756. eCollection 2015.

Supplemental Content

Support Center